Effect of low molecular weight heparin and different heparin molecular weight fractions on the activity of the matrix-degrading enzyme aggrecanase: Structure-function relationship

Journal of Cellular Biochemistry

Volumn 95, Issue 1, 2005, Pages 95-98

  Mousa, Shaker A ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Aggrecanase; Anti inflammatory; Anticancer; Heparin; Inflammation; Invasion; Low molecular weight heparin

Indexed keywords

AGGRECANASE; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; STREPTAVIDIN; TINZAPARIN; DALTEPARIN; PROTEINASE; PROTEINASE INHIBITOR;

ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BIOTINYLATION; CARTILAGE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING; DRUG EFFECT; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; EXTRACELLULAR MATRIX; INFLAMMATION; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; ANIMAL; CATTLE; CHEMISTRY; COMPARATIVE STUDY; ENZYME ACTIVATION;

ANIMALS; CATTLE; DALTEPARIN; ENDOPEPTIDASES; ENOXAPARIN; ENZYME ACTIVATION; PROTEASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 23844432006     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.20398     Document Type: Article

References (10)

1. DiMicco MA, Patwari P, Siparsky PN, Kumar S, Pratta MA, Lark MW, Kim YJ, Grodzinsky AJ. 2004. Mechanisms and kinetics of glycosaminoglycan release following in vitro cartilage injury. Arthritis Rheum 50:840-848.
2. Hughes CE, Caterson B, Fosang AJ, Roughley PJ, Mort JS. 1995. Monoclonal antibodies that specifically recognize neoepitope sequences generated by aggrecanase and MMP cleavage of aggrecan: Application to catabolism in situ and in vivo. Biochem J 305:799-804.
3. Miller JA, Liu RQ, Davis GL, Pratta MA, Trzaskos JM, Copeland RA. 2003. A microplate assay specific for the enzyme aggrecanase. Anal Biochem 314:260-265.
4. Mousa S. 2002. The low molecular weight heparin, tinzaparin, in thrombosis and beyond. Cardiovasc Drug Rev 20:199-216.
5. Mousa SA, Bozarth J, Barrett JS. 2003. Pharmacodynamic properties of the low molecular weight heparin, tinzaparin. Effect of molecular weight distribution on plasma tissue factor pathway inhibitor in healthy human subjects. J Clin Pharmacol 43:2-9.
6. Munteanu SE, Ilic MZ, Handley CJ. 2002. Highly sulfated glycosaminoglycans inhibit aggrecanase degradation of aggrecan by bovine articular cartilage explant cultures. Matrix Biol 21:429-440.
7. Okada Y. 2000. Tumor cell-matrix interaction. Pericellular matrix degradation and metastasis. Verh Dtsch Ges Pathol 84:33-42.
8. Sandy JD, Flannery CR, Neame PJ, Lohmander LS. 1992. The structure of aggrecan fragments in human synovial fluid: Evidence for the involvement in osteoarthritis of a novel proteinease, which cleaves the Glu373-Ala 374 bond in the interglobular domain. J Clin Invest 89:1512-1516.
9. Tortorella MD, Pratta M, Liu RQ, Abbaszade I, Ross H, Burn T, Arner E. 2000. The thrombspondin motif of aggrecanase-1 is critical for aggrecan substrate recognition and cleavage. J Biol Chem 275:25791-25797.
10. Westling J, Fosang AJ, Last K, et al. 2002. ADAMTS4 cleaves at the aggrecanase site (Glu373-Ala374) and secondarily at the matrix metalloproteinase site (Asn341-Phe342) in the aggrecan interglobular domain. J Biol Chem 277:16059-16066.